Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma.

Pantazopoulos I, Boura P, Xanthos T, Syrigos K.

Eur Respir J. 2013 Mar;41(3):706-15. doi: 10.1183/09031936.00226111. Epub 2012 Jul 26. Review.

2.

Serum and pleural fluid biomarkers for mesothelioma.

Creaney J, Robinson BW.

Curr Opin Pulm Med. 2009 Jul;15(4):366-70. doi: 10.1097/MCP.0b013e32832b98eb. Review.

PMID:
19417672
3.

Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.

Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Grégoire M, Porte H, Copin MC, Lassalle P.

Clin Cancer Res. 2007 May 15;13(10):2928-35.

4.

Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.

Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ, Robinson BW.

J Thorac Oncol. 2008 Aug;3(8):851-7. doi: 10.1097/JTO.0b013e318180477b.

5.

Biomarkers for mesothelioma.

Scherpereel A, Lee YC.

Curr Opin Pulm Med. 2007 Jul;13(4):339-443. Review.

PMID:
17534183
6.

Clinical utility of diagnostic markers for malignant pleural mesothelioma.

Grigoriu BD, Grigoriu C, Chahine B, Gey T, Scherpereel A.

Monaldi Arch Chest Dis. 2009 Mar;71(1):31-8. Review. Erratum in: Monaldi Arch Chest Dis. 2009 Jun;71(2):88.

PMID:
19522163
7.

Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos.

Bayram M, Dongel I, Akbaş A, Benli I, Akkoyunlu ME, Bakan ND.

Lung. 2014 Feb;192(1):197-203. doi: 10.1007/s00408-013-9526-9. Epub 2013 Oct 30.

PMID:
24170217
8.

Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?

Creaney J, Yeoman D, Musk AW, de Klerk N, Skates SJ, Robinson BW.

Lung Cancer. 2011 Oct;74(1):55-60. doi: 10.1016/j.lungcan.2011.02.007. Epub 2011 Mar 12.

PMID:
21397972
9.

Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.

Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, Nilsen TI, Robinson B, Kjaerheim K.

Lung Cancer. 2008 Aug;61(2):235-43. doi: 10.1016/j.lungcan.2007.12.025. Epub 2008 Feb 20.

PMID:
18281122
10.

Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma.

Creaney J, Dick IM, Segal A, Musk AW, Robinson BW.

Lung Cancer. 2013 Dec;82(3):491-8. doi: 10.1016/j.lungcan.2013.09.016. Epub 2013 Oct 9.

PMID:
24161718
11.

[Other thoracic cancers. Malignant pleural mesothelioma: biology and diagnosis].

Scherpereel A, Grigoriu BD, Astoul P.

Rev Mal Respir. 2008 Oct;25(8 Pt 2):3S183-90. French.

PMID:
18971844
12.

Mesothelin and osteopontin.

Pantazopoulos I, Xanthos T, Boura P, Syrigos K.

Eur Respir J. 2013 Aug;42(2):557-8. doi: 10.1183/09031936.00064413. No abstract available.

13.

Mesothelin and osteopontin.

Hillerdal G.

Eur Respir J. 2013 Aug;42(2):557. doi: 10.1183/09031936.00052213. No abstract available.

14.

Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers.

Felten MK, Khatab K, Knoll L, Schettgen T, Müller-Berndorff H, Kraus T.

Int Arch Occup Environ Health. 2014 Feb;87(2):195-204. doi: 10.1007/s00420-013-0853-1. Epub 2013 Feb 20.

PMID:
23423281
15.

[New diagnostic markers for malignant pleural mesothelioma].

Grigoriu BD, Grégoire M, Chahine B, Scherpereel A.

Bull Cancer. 2008 Feb;95(2):177-84. doi: 10.1684/bdc.2008.0576. Review. French.

16.

Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma.

Sato T, Suzuki Y, Mori T, Maeda M, Abe M, Hino O, Takahashi K.

Cancer Med. 2014 Oct;3(5):1377-84. doi: 10.1002/cam4.297. Epub 2014 Jul 10.

17.

Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.

Hollevoet K, Nackaerts K, Thimpont J, Germonpré P, Bosquée L, De Vuyst P, Legrand C, Kellen E, Kishi Y, Delanghe JR, van Meerbeeck JP.

Am J Respir Crit Care Med. 2010 Mar 15;181(6):620-5. doi: 10.1164/rccm.200907-1020OC. Epub 2010 Jan 14.

PMID:
20075387
18.

Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum.

Creaney J, Sneddon S, Dick IM, Dare H, Boudville N, Musk AW, Skates SJ, Robinson BW.

Dis Markers. 2013;35(2):119-27. doi: 10.1155/2013/874212. Epub 2013 Aug 6.

19.

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.

Creaney J, Dick IM, Meniawy TM, Leong SL, Leon JS, Demelker Y, Segal A, Musk AW, Lee YC, Skates SJ, Nowak AK, Robinson BW.

Thorax. 2014 Oct;69(10):895-902. doi: 10.1136/thoraxjnl-2014-205205. Epub 2014 Jul 18.

20.

Supplemental Content

Support Center